• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psilocybin vs Escitalopram for Depression

Psilocybin vs Escitalopram for Depression

September 10, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Carhart-Harris R et al, New Engl J Med 2021;384(15):1402–1411

STUDY TYPE: Randomized controlled trial

Psilocybin is, among other things, a serotonin 2A agonist responsible for the psychedelic properties of magic mushrooms. Back in 1960, Sandoz (now Novartis) began marketing psilocybin to enhance the effects of psychotherapy, but production was stopped soon after due to concerns about its abuse liability and potential to induce psychosis. Now, over a half-century later, the FDA has granted psilocybin breakthrough status and fast-tracked research to explore its potential antidepressant effects. Those effects have been associated with psilocybin’s ability to induce transcendent spiritual states. Similar to how it was used in the 1960s, modern-day psilocybin is delivered along with supportive psychotherapy to enhance those beneficial effects while maintaining close oversight in case patients experience a “bad trip.”

In this double-blind study, investigators randomized 59 patients with moderate to severe depression to receive either psilocybin 25 mg (given twice: on day 1 and on day 21) or escitalopram 10–20 mg/day over the course of six weeks. Importantly, most patients included in the trial were not treatment resistant, having taken on average only two psychotropic medications in the past. Although there was no placebo group, the escitalopram group received a microdose of psilocybin so all patients could be informed that they were receiving it—a clever maneuver that aimed to standardize expectations.

The primary outcome of interest was reduction in scores on the 16-item Quick Inventory of Depression Symptomatology-Self Report (QIDS). Both groups improved, with overall scores favoring psilocybin over escitalopram: 8- versus 6-point reduction in depression scores on the QIDS and response rates of 70% versus 48%. However, these differences were not statistically significant.

On questioning, patients receiving psilocybin reported greater perceived improvements “in the ability to cry and feel compassion, intense emotions, and pleasure.” Adverse effects were similar between the two groups, and there were no reports of perceptual changes, psychosis, or other serious problems with psilocybin.

TCPR’S TAKE
The study ostensibly shows that psilocybin is as effective as escitalopram for depression. However, the research suffers from two major flaws. First, the researchers failed to assess the integrity of the blind. Given that patients were mostly self-referred and highly motivated, and that 72% had used psilocybin in the past, they could very possibly have guessed whether they were receiving a therapeutic dose of psilocybin. Second, lacking a placebo group, we can’t know whether psilocybin even worked. Nearly 50% of SSRI trials fail to separate from placebo, and that’s with sample sizes 10 times larger than the ones used in this study. It’s possible that neither psilocybin nor escitalopram were effective.

The New England Journal of Medicine rarely publishes psychiatric research, and with the level of interest surrounding psilocybin, you will no doubt hear more about this pilot study. Unfortunately, the study fails to move the needle much, and it would be premature to recommend psilocybin to your patients until larger, placebo-controlled studies are conducted.

Related content: When Psilocybin was a Psych Med

General Psychiatry
KEYWORDS antidepressant-augmentation antidepressants depression depressive_disorder novel-medications psilocybin treatment-resistant-depression
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: September 10, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Genetic Testing in Depression
    Desert Island Diagnoses
    Atomoxetine: Myths and Truths
    Overdiagnosis in Psychiatry
    Psilocybin vs Escitalopram for Depression
    Pilot Study of Ketamine vs ECT for Major Depression
    CME Post-Test - Overdiagnosis, TCPR, September 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.